Macimorelin

Macimorelin

Names
IUPAC name 2-Amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
Other names Aib-Trp-gTrp-CHO; AEZS-130; JMV 1843; Macimorelin acetate
Identifiers
CAS Number	381231-18-1 945212-59-9 (acetate)
3D model (Jmol)	Interactive image
ChemSpider	7980698
PubChem	9804938
InChI InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1 Key: UJVDJAPJQWZRFR-DHIUTWEWSA-N InChI=1/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1 Key: UJVDJAPJQWZRFR-DHIUTWEWBN
SMILES CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@H](CC3=CNC4=CC=CC=C43)NC=O)N
Properties
Chemical formula	C26H30N6O3
Molar mass	474.57 g·mol^−1
Pharmacology
ATC code	V04CD06 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Macimorelin (INN) is a drug being developed by Æterna Zentaris for use in the diagnosis of adult growth hormone deficiency. As of January 2014, it is in Phase III clinical trials.^[1]

Macimorelin is a mimic of ghrelin, a growth hormone secretagogue. It binds to the growth hormone secretagogue receptor (GHSR) causing release of growth hormone from the pituitary gland.^[2][3][4]

See also

• Anamorelin
• Capromorelin
• Examorelin (hexarelin)
• GHRP-6 (SKF-110679)
• Ibutamoren (MK-677)
• Ipamorelin
• Pralmorelin (GHRP-2)
• Relamorelin
• SM-130,686
• Tabimorelin

References

1. "Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA". Wall Street Journal. January 6, 2014.
2. "Macimorelin". NCI Drug Dictionary. National Cancer Institute.
3. Koch, Linda (2013). "Growth hormone in health and disease: Novel ghrelin mimetic is safe and effective as a GH stimulation test". Nature Reviews Endocrinology. 9 (6): 315. doi:10.1038/nrendo.2013.89.
4. Garcia, J. M.; Swerdloff, R.; Wang, C.; Kyle, M.; Kipnes, M.; Biller, B. M. K.; Cook, D.; Yuen, K. C. J.; Bonert, V.; Dobs, A.; Molitch, M. E.; Merriam, G. R. (2013). "Macimorelin (AEZS-130)-Stimulated Growth Hormone (GH) Test: Validation of a Novel Oral Stimulation Test for the Diagnosis of Adult GH Deficiency". Journal of Clinical Endocrinology & Metabolism. 98 (6): 2422. doi:10.1210/jc.2013-1157.